Latigo Biotherapeutics, Inc. (LTGO) stock
LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.24−0.07 (-0.53%)
Close on Nov 19, 2026Market cap $877.80MP/E –Yield 0.00%
Latigo Biotherapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$19.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -$19.91M | – |
See a number that looks wrong?